Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05292768

Are Mast Cells Involved in Autoinflammatory Diseases

Autoinflammatory diseases (AID) are caused by innate immunity dysregulation. AID pathophysiology is only partly understood, especially in the case of unclassified AID. Mast cells (MC) are innate immune cells associated with a spectrum of disease between systemic mastocytosis and mast cell activation syndrome. The implication of MC has been shown in cryopyrin associated periodic syndrome (CAPS).Our aim is to evaluate the involvement of MC in AID by assessing clinical and biological signs of MC activation and studying cutaneous and digestive biopsies.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Autoinflammatory diseases (AID) are caused by innate immunity dysregulation and characterized by recurrent bouts of fever, frequently associated with digestive, articular or cutaneous symptoms, and sometimes ocular, auricular or neurologic inflammation. The most frequent monogenic AID is Familial Mediterranean fever (FMF).

Despite recent genetic progress AID pathophysiology is only partly understood, especially in the case of unclassified AID.

Mast cells (MC) are innate immune cells associated with a spectrum of disease between systemic mastocytosis and mast cell activation syndrome (MCAS). In MCAS, patients have various symptoms including abdominal pain, bloating, pruritus, flush, anxiety, fatigue, among which some are similar to those seen in patients with AID. The implication of MC has been shown in cryopyrin associated periodic syndrome (CAPS).

Our hypothesis is that MC could be involved in AID pathophysiology,

In order to test this hypothesis, we plan to study :

  • clinical MC activation symptoms via a standardized clinical score
  • biological MC mediators : by measuring total serum tryptase and histamine in total blood, plasma and urine
  • MC infiltration on gastro-intestinal (GI) tract and cutaneous biopsies We will compare clinical MC activation score in AID patients to patients with mastocytosis, with other inflammatory diseases, and with healthy controls.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients >18 years old with Auto-inflammatory diseases already followed up at the CeRéMAIA (french national reference center for autoinflamamtory diseases and AA amyloidosis) of Tenon hospital and included in the JIRcohorte
  • Healthy adult controls, age- and sex-matched with MAI patients, and controls with mastocytosis, an immuno-inflammatory disease.
  • Subject affiliated to or entitled to a social security scheme
  • Collection of the patient's or healthy control's non-opposition

Exclusion criteria

  • Subjects unable to answer questions or express themselves
  • Subjects who do not speak French
  • Subject deprived of liberty or under legal protection.

Treatment and study plan

Primary outcomes

  1. : presence of MCAS

    Time frame: at inclusion

    presence of clinical and biological markers of MCAS

Secondary outcomes

  1. comparison of clinical symptoms of MC activation between groups

    Time frame: at inclusion

    we will compare clinical symptoms of MC activation between AID patients and other groups

  2. MC mediators associated to AID

    Time frame: at inclusion

    determine which MC mediators are elevated in AID and if they correlate with inflammation

  3. MC infiltration in biopsies from AID patients

    Time frame: at inclusion, retrospectively

    we will study MC infiltration in digestive, renale and cutaneous biopsies from patients with AID and compare them with biopsies from the other groups from subgroups of patients who had a biopsy performed.

  4. basophilic polynuclear activation in AID patients

    Time frame: at inclusion, retrospectively

    we will study basophilic polynuclear activation from blood samples of AID patients

Study contacts

Contact information is provided by the study sponsor or research team.

Nabiha Sbeih, MD

CONTACT

[email protected]

+33 (0)1 84 82 74 03

Sophie GEORGIN-LAVIALLE, PU-PH

CONTACT

[email protected]

+33 (0)1 56 01 72 04 or 60 77

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • Institut Imagine

Registry information

Acronym: INFLAMAST

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Mar 23, 2022
Registry last updated
Mar 23, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.